Senzime Valuation
Is SEZI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SEZI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SEZI (SEK5.71) is trading above our estimate of fair value (SEK1.75)
Significantly Below Fair Value: SEZI is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SEZI?
Key metric: As SEZI is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is SEZI's PS Ratio? | |
|---|---|
| PS Ratio | 11.7x |
| Sales | SEK 55.29m |
| Market Cap | SEK 647.15m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 11.2x |
| Enterprise Value/EBITDA | -4.7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does SEZI's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.6x | ||
ADDV A ADDvise Group | 1.2x | 8.5% | SEK 727.8m |
ORT B Ortoma | 6.6x | 46.2% | SEK 419.0m |
CRAD B C-Rad | 2x | 14.8% | SEK 948.6m |
CARE Careium | 0.8x | 10.2% | SEK 705.5m |
SEZI Senzime | 11.7x | 71.9% | SEK 647.1m |
Price-To-Sales vs Peers: SEZI is expensive based on its Price-To-Sales Ratio (11.7x) compared to the peer average (2.6x).
Price to Sales Ratio vs Industry
How does SEZI's PS Ratio compare vs other companies in the SE Medical Equipment Industry?
Price-To-Sales vs Industry: SEZI is expensive based on its Price-To-Sales Ratio (11.7x) compared to the Swedish Medical Equipment industry average (4.4x).
Price to Sales Ratio vs Fair Ratio
What is SEZI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 11.7x |
| Fair PS Ratio | 15x |
Price-To-Sales vs Fair Ratio: SEZI is good value based on its Price-To-Sales Ratio (11.7x) compared to the estimated Fair Price-To-Sales Ratio (15x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | SEK 5.71 | SEK 12.25 +114.5% | 2.0% | SEK 12.50 | SEK 12.00 | n/a | 2 |
| Nov ’25 | SEK 6.40 | SEK 12.25 +91.4% | 2.0% | SEK 12.50 | SEK 12.00 | n/a | 2 |
| Oct ’25 | SEK 6.46 | SEK 12.25 +89.6% | 2.0% | SEK 12.50 | SEK 12.00 | n/a | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Arcoma
SEK 146.4m
Develops, produces, and provides radiology solutions worldwide.
ARCOMA
SEK 11.10
7D
2.8%
1Y
49.0%
Mentice
SEK 560.0m
Provides endovascular simulation technology solutions in Europe, the Middle East, Africa, Asia, the Asia Pacific region, and the Americas.
MNTC
SEK 21.90
7D
2.8%
1Y
-46.6%
Dignitana
SEK 95.8m
A medical technology company, engages in the development, production, and marketing of medical cooling devices in the United States and internationally.
DIGN
SEK 1.19
7D
3.5%
1Y
-45.9%